Verrica Pharmaceuticals Inc (VRCA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.30-1.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improves from -$9.7 million in Q1 2026: metric not reported.
Verrica aims to grow revenue to about $30 million in 2025. The company tries to improve its operating income from a loss of $9.7 million. Recent earnings beats show some progress. The stock is cheap compared to peers.
Verrica is still losing money with worsening operating income. Revenue growth is uncertain and below analyst expectations. The stock price has dropped 28% from its high.
The market expects about 16% revenue growth. Our fair value is near $21.75, reflecting a cheap valuation versus peers. We see risk in the company’s ability to improve profits.
Breaks if: EPS loss worsens beyond -$1.73 in FY26
Breaks if: Operating loss worsens beyond -$9.7 million in Q1 2026
Revenue falls below $30 million in FY25
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating a high-risk environment while focusing on expanding its commercial sales and advancing clinical programs.
The market appears to have priced in a low expectations gap, indicating that VRCA is seen as relatively cheap compared to its peers. However, there is a significant divergence in performance expectations, reflecting the company's recent earnings challenges.
Fundamentals are likely to remain under pressure in the near term due to weak recent financial performance. Management is making progress in expanding sales and advancing clinical trials, but the overall earnings quality remains loss-making.
The thesis hinges on the company's ability to maintain momentum in its commercial sales and successfully advance its clinical programs. Additionally, broader sector performance and economic indicators, such as job reports, will play a crucial role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, VRCA's performance will depend on its execution of key priorities and the overall health of the healthcare sector. Not investment advice.